PHE Scientific Advisor Anupam Jena was recently featured on the award-winning podcast Freakonomics, as part of their “Bad Medicine: The Story of 98.6” 3-part series. Episode one addresses some of the historical mistakes produced by “trial and error” medicine, and asks whether the new era of evidence-based medicine is the solution. Dr. Jena is featured in the first and third episodes of the series.
Precision for Value’s Dominic Galante and Maureen Hennessey discuss the subject of patient engagement tools with Keith Loria from Medical Economics, and why more physicians aren’t using them.
Precision Health Economics’ senior research economist Jason Shafrin discusses value-based drug pricing and the benefits for payers in HealthcareDIVE.
Dan Renick, President of global market access specialists Precision for Value, explains “the wedge strategy”in a new article for STAT News.
Academic and Industry Leaders Launch Initiative to Advance Value Measurement
Innovation and Value Initiative to apply advanced scientific methodologies and multi-sector leadership to improve value measurement in healthcare
Bethesda, MD, September 28, 2016 – Precision Health Economics today launched the Innovation and Value Initiative (IVI), a multi-stakeholder scientific initiative to advance the way value is measured and rewarded in the healthcare marketplace.
Precision Health Economics’ Scientific Advisor Amitabh Chandra is interviewed on the subject of precision medicine pricing, in a new Q&A for STAT News.
On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.
On the panel, Precision Health Economics’ Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality runs in the opposite direction. He noted potential flaws in value-based pricing and a one-size-fits-all-approach to global drug development and argued for more robust credit markets in health care.
Precision for Value thought leader Jeremy Schafer was recently interviewed by BioPharm Insight’s Reynald Castaneda, providing his perspective into projected competition in the biosimilar marketplace.
Precision Health Economics’ Darius Lakdawalla speaks with the AP’s Matthew Perrone and offers some guidelines for drug pricing.
Precision for Value’s Dan Renick offers his perspective on GSK’s Breo in The Pink Sheet.